Sarilumab
Monoclonal antibody
Evidence outlook
Approved: Rheumatoid Arthritis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Systemic Juvenile Idiopathic Arthritis · Phase 2
Also approved (4)
- Polymyalgia Rheumatica (PMR) KEVZARA is indicated for treatment of adult patients with polymyalgia rheumatica who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.
- Polyarticular Juvenile Idiopathic Arthritis (pJIA) KEVZARA is indicated for treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients who weigh 63 kg or greater.
- Treatment of rheumatoid arthritis in patients who have not responded sufficiently to conventional treatments
- Rheumatoid arthritisKevzara in combination with methotrexate (MTX) is indicated for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Kevzara can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate. Polymyalgia rheumaticaKevzara is indicated for the treatment of polymyalgia rheumatica (PMR) in adult patients who have had an inadequate response to corticosteroids or who experience a...
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
RA-MOBILITY NCT01061736 · Rheumatoid Arthritis This was a large, randomized, triple-blind, placebo-controlled trial with adequate sample size and hard clinical/functional/radiographic primary endpoints (ACR20 response, HAQ-DI, and van der Heijde-modified Total Sharp Score). In the confirmatory Part B, both sarilumab 150 mg and 200 mg every 2 weeks met all three primary endpoints with highly significant differences from placebo (p<0.0001), and Part A also showed significant ACR20 responses for several sarilumab doses. The positive, well-designed confirmatory results support strong evidence for sarilumab. Registry: NCT01061736 | 2/3 | Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline to Week 12); Part B: Percentage of Participants Achieving ACR20 Response at Week 24 (Baseline to Week 24); Part B: Change From Baseline in Health Assessment Question Disability Index (HAQ-DI) at Week 16 (Baseline, Week 16); Part B: Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 52 (Baseline, Week 52) 2013-10 | Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline to Week 12): Part A: SAR 100 mg qw 62% | Part A: SAR 150 mg qw 72% | Part A: SAR 100 mg q2w 49% | Part A: SAR 150 mg q2w 66.7% | Part A: SAR 200 mg q2w 65.4% vs Part A: Placebo qw 46.2% | Reliable signal | link ↗ |
View 3 more trials
SARIL-RA-EXTEND NCT01146652 · Rheumatoid Arthritis This is an open-label, non-randomized long-term extension study of patients who completed prior sarilumab randomized trials (e.g., EFC11072, ACT11575, EFC10832, SFY13370, EFC13752). All 2023 participants received sarilumab, either with DMARDs (n=1912) or as monotherapy (n=111), and the primary outcomes were safety counts (TEAEs/SAEs) and device usability, with no formal statistical comparison between treatment groups. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)" (with 4 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak. Registry: NCT01146652 | 3 | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (From first dose (i.e., Day 1 of study LTS11210) up to 60 days after last dose (maximum duration: up to 523 weeks)); Sub-study: Number of Participants Reported Product Technical Complaints (PTC), Product Technical Failures (PTF) and/or Failed Drug Deliveries (FDD) With Pre-filled Syringe With Safety System (From Week 24 to 36); Sub-study: Number of Product Technical Complaints - Product Technical Failures With Pre-filled Syringe With Safety System (From Week 24 to 36); Sub-study: Number of Failed Drug Deliveries Associated With Pre-filled Syringe With Safety System (From Week 24 to 36); Sub-study: Number of Product Technical Complaints With Pre-filled Syringe With Safety System (From Week 24 to 36) 2020-12-31 | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (From first dose (i.e., Day 1 of study LTS11210) up to 60 days after last dose (maximum duration: up to 523 weeks)): Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) — Any TEAE: 1760 Participants; Any TE SAE: 617 Participants | Sarilumab Monotherapy — Any TEAE: 98 Participants; Any TE SAE: 27 Participants | Weak signal | link ↗ |
SARIL-RA-MONARCH NCT02332590 · Rheumatoid Arthritis This was a randomized, quadruple-blind, active-controlled Phase 3 trial in 369 adults with rheumatoid arthritis comparing sarilumab 200 mg every 2 weeks with adalimumab 40 mg every 2 weeks for 24 weeks. The primary endpoint — change in DAS28-ESR from baseline to Week 24 — was statistically significant in favor of sarilumab (difference -1.077, p<0.0001). A well-powered, fully blinded trial with an active comparator that met its hard clinical primary endpoint provides strong evidence for the primary comparison. Registry: NCT02332590 | 3 | DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24 (Baseline, Week 24) 2016-01-20 | DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24 (Baseline, Week 24): Sarilumab 200 mg/Sarilumab 200 mg -3.28 units on a scale (Standard Error 0.105) vs Adalimumab 40 mg/Sarilumab 200 mg -2.2 units on a scale (Standard Error 0.106) | Reliable signal | link ↗ |
SARIL-RA-TARGET NCT01709578 · Rheumatoid Arthritis Registry: NCT01709578 | 3 | Percentage of Participants Who Achieved at Least 20% Improvement in the American College of Rheumatology (ACR20) Criteria at Week 24; Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12 (Baseline, Week 12) 2015-03 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (15)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (17)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (2)
What this study did
What this study did
Used as active comparator (2)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (2)
What this study did
What this study did
Appears in other studies (6)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2/3 (1)
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Competitive landscape
Other IL-6 receptor drugs
BAT1806, tocilizumab, Levilimab. Compare all 4 IL-6 receptor drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Rheumatoid Arthritis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Sarilumab: this drug | Approved | Monoclonal antibody | IL-6 receptor | Reliable signal | NCT02332590: DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24 (Baseline, Week 24): Sarilumab 200 mg/Sarilumab 200 mg -3.28 units on a scale (Standard Error 0.105) vs Adalimumab 40 mg/Sarilumab 200 mg -2.2 units on a scale (Standard Error 0.106) NCT01061736: Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline to Week 12): Part A: SAR 100 mg qw 62% | Part A: SAR 150 mg qw 72% | Part A: SAR 100 mg q2w 49% | Part A: SAR 150 mg q2w 66.7% | Part A: SAR 200 mg q2w 65.4% vs Part A: Placebo qw 46.2% | |
| Abatacept (Orencia) | Approved | Protein / enzyme therapeutic | CD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cells | Reliable signal | NCT00048568: Number of American College of Rheumatology 20 (ACR 20) Responders at Day 169 (Day 169): ABA + MTX DB 288/424 (67.9%) vs MTX + Placebo DB 85/214 (39.7%) NCT00048581: Double-blind Period (DB); Number of Participants With American College of Rheumatology (ACR) 20 Response at Day 169 (Day 169): Abatacept (ABA) 129/256 (50.4%) vs Placebo (PLA) 26/133 (19.5%) | |
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | NCT00195702: Primary 1, ACR20 at week 24: 63% (40 mg every other week) and 61% (20 mg weekly) vs 30% placebo, all with methotrexate (P<=0.001 for each), met. Primary 2, change in modified total Sharp score at week 52: 0.1 and 0.8 vs 2.7 (P<=0.001 for each), met. Primary 3, change in HAQ disability index at week 52: -0.59 and -0.61 vs -0.25 (P<=0.001 for each), met. | |
| Adalimumab-Aacf (Idacio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aaty (Yuflyma) | Approved | Monoclonal antibody | TNF-alpha | Partial signal | NCT03789292: ACR20 response at week 24, CT-P17 vs EU-adalimumab (ITT): 82.7% (268/324) in both groups; treatment difference 95% CI -5.94 to 5.94 (margin -15 to 15%) and 90% CI -4.98 to 4.98 (margin -12 to 15%), both within the predefined equivalence margins (Kay 2021, Arthritis Res Ther). | |
| Adalimumab-Adaz (Hyrimoz) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | No reviewed efficacy summary in this indication | |
| Adalimumab-Afzb (Abrilada) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | NCT02480153: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1 (Week 12): Period 1: PF-06410293 68.35% vs Period 1: Adalimumab-EU 71.33% | |
| Adalimumab-Aqvh (Yusimry) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Atto (Amjevita) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | Featured results are non-efficacy only in this race | |
| Adalimumab-Bwwd (Hadlima) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Fkjp (Hulio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Ryvk (Simlandi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Anakinra | Approved | Protein / enzyme therapeutic | Interleukin-1 Receptor Antagonist | Weak signal | No reviewed efficacy summary in this indication | |
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | Reliable signal | NCT02265705: ACR20 response at Week 12 (primary endpoint, 290 randomized, 145 per arm): 58.6% baricitinib 4mg vs 28.3% placebo (OR 4.1, 95% CI 2.5-6.9; p=0.001) NCT01710358: ACR20 response at Week 12 (primary endpoint): 70% baricitinib 4mg vs 40% placebo (P<0.001) | |
| BAT1806 (Tofidence) | Approved | Monoclonal antibody | IL-6 receptor | Partial signal | NCT03830203: ACR20 response rate at week 24: 67.9% reference tocilizumab vs 69.9% BAT1806/BIIB800; treatment difference 1.9% (90% CI -4.0 to 7.9), within predefined equivalence margins | |
| Certolizumab Pegol (Cimzia) | Approved | Antibody fragment | TNF-alpha | Weak signal | Featured results are non-efficacy only in this race | |
| CT-P47 (tocilizumab) (Avtozma) | Approved | Monoclonal antibody | IL-6R antagonist | Reliable signal | NCT05489224: Mean Change From Baseline in Disease Activity Score 28 (DAS28) Using Erythrocyte Sedimentation Rate (ESR) at Week 24 (Week 24): CT-P47 -3.77 units on a scale (Standard Error 0.12) vs RoActemra -3.67 units on a scale (Standard Error 0.118) NCT05725434: 12-week, single-arm, open-label Phase 3 usability study: Post-Self-Injection Assessment Questionnaire (POST-SIAQ) domain scores at Week 2 exceeded 8/10 for all domains except self-confidence (7.11) and satisfaction with self-injection (7.98); the study is reported to have met its primary usability endpoint, with no autoinjector malfunctions and no new safety signals. | |
| Etanercept (Enbrel) | Approved | Protein / enzyme therapeutic | TNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha) | Partial signal | NCT03780959: Percentage of Participants With Disease Flare in Part 2 (End of part 1 (day 90) and months 4 to 7): Part 2: Etanercept 0.4 mg/kg 28% vs Part 2: Placebo 81% | |
| Golimumab (Simponi) | Approved | Monoclonal antibody | TNF-alpha | Partial signal | NCT00264550: Co-primary 1, ACR20 response at week 14 vs placebo plus methotrexate (44/133, 33.1%): combined golimumab plus methotrexate 99/178 (55.6%), p<0.001, the prespecified primary test, met; golimumab 50 mg plus methotrexate 49/89 (55.1%), p=0.001; golimumab 100 mg plus methotrexate 50/89 (56.2%), p<0.001. Co-primary 2, median HAQ improvement at week 24 vs placebo plus methotrexate (0.125): combined golimumab plus methotrexate 0.4375, p<0.001, met; 50 mg plus methotrexate 0.375, p<0.001; 100 mg plus methotrexate 0.500, p<0.001. Golimumab 100 mg alone vs placebo plus methotrexate (for ACR20, tested only after a positive primary test): ACR20 59/133 (44.4%), p=0.059; HAQ 0.125, p=0.240; not significant. NCT00264537: ACR50 response at Week 24: placebo+MTX 47/160 vs combined golimumab+MTX (50mg or 100mg)+MTX 122/318; CMH p=0.053. Individually: golimumab 50mg+MTX 64/159 vs placebo+MTX 47/160, p=0.042; golimumab 100mg+MTX 58/159 vs placebo+MTX, p=0.177. | |
| Hydroxychloroquine | Approved | Small molecule | Autophagy/lysosomal acidification | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab (Remicade) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | No reviewed efficacy summary in this indication | |
| Infliximab-Abda (Renflexis) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Axxq (Avsola) | Approved | Monoclonal antibody | TNF-alpha | Partial signal | Featured results are non-efficacy only in this race | |
| Infliximab-Dyyb (Inflectra) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | Featured results are pharmacokinetic only in this race | |
| Infliximab-Qbtx (Ixifi) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | NCT02222493: Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1 (Week 14): Period 1: PF-06438179 198/324 (61.1%) vs Period 1: Infliximab-EU Remicade (INX) 207/326 (63.5%) | |
| Methotrexate | Approved | Small molecule | Dihydrofolate reductase (DHFR), Folate Analog Metabolic Inhibitor | Partial signal | NCT01185301: DAS28(CRP) < 3.2 at week 26 with adalimumab plus methotrexate 2.5, 5, 10 or 20 mg/week: 42.9%, 44.0%, 56.6% and 60.2% (n=98 to 100 per arm); statistically significant increasing trend with dose (Burmester et al., Ann Rheum Dis 2015). | |
| Methylprednisolone | Approved | Small molecule | Glucocorticoid receptor agonist | not yet graded | No reviewed efficacy summary in this indication | |
| PF-05280586 | Approved | Biologic (subtype unspecified) | CD20 | Partial signal | Featured results are pharmacokinetic only in this race | |
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Rituximab (Rituxan) | Approved | Monoclonal antibody | CD20, CD20-directed Cytolytic Antibody | Reliable signal | NCT00299130: Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Rituximab 2 x 0.5 g + MTX 54.5% | Rituximab 2 x 1.0 g + MTX 50.6% vs Placebo + MTX 23.3% NCT00468546: ACR20 response at week 24: 51.3% (153/298) with rituximab + methotrexate vs 17.9% (36/201) with placebo + methotrexate. | |
| Rituximab-Abbs (Truxima) | Approved | Monoclonal antibody | CD20 | Reliable signal | NCT02149121: Primary efficacy: DAS28-CRP change from baseline -2.11 with CT-P10 vs -2.10 with reference products; treatment difference -0.01 (90% CI -0.22 to 0.20), with an equivalence margin of ±0.50. Primary PK AUC0-last ratio: 97.07% (CT-P10/Rituxan; 90% CI 88.08% to 106.99%) and 94.18% (CT-P10/MabThera; 90% CI 85.40% to 103.86%). | |
| Sulfasalazine | Approved | Small molecule | Aminosalicylate | not yet graded | No reviewed efficacy summary in this indication | |
| Tocilizumab (Actemra / RoActemra) | Approved | Monoclonal antibody | IL-6 receptor | Reliable signal | NCT03155347: ACR20 response at Week 24: tocilizumab+methotrexate 52.9% (72/136) vs methotrexate alone 25.0% (17/68), difference 27.9pp (95% CI 14.7-41.2), P<.001; tocilizumab monotherapy 50.0% (68/136) vs methotrexate alone 25.0%, difference 25.0pp (95% CI 11.7-38.3), P<.001 NCT01232569: Percentage of Patients With an American College of Rheumatology 20 (ACR20) Response at Week 24 (Baseline to Week 24): Tocilizumab 162 mg sc 60.9% (95% CI 56.3 to 65.4) vs Placebo sc 31.5% (95% CI 25.4 to 37.7) | |
| Tofacitinib (Xeljanz) | Approved | Small molecule | JAK, JAK1/JAK3 | Weak signal | Featured results are non-efficacy only in this race | |
| Upadacitinib (Rinvoq) | Approved | Small molecule | JAK, JAK1 | Reliable signal | NCT03086343: Change from baseline DAS28-CRP at week 12: -2.52 (95% CI -2.66 to -2.37) upadacitinib vs -2.00 (95% CI -2.14 to -1.85) abatacept; upadacitinib met primary non-inferiority and key secondary superiority endpoints. NCT02706873: Co-primary endpoints: ACR50 at Week 12 -- upadacitinib 15mg 52% (95% CI 47-58), 30mg 56% (95% CI 51-62), MTX 28% (95% CI 23-33), P<0.001 for both doses vs MTX. DAS28-CRP<2.6 at Week 24 -- upadacitinib 15mg 48% (95% CI 43-54), 30mg 50% (95% CI 45-56), MTX 19% (95% CI 14-23), P<0.001 for both doses vs MTX | |
| Acellbia | Phase 3 | Monoclonal antibody | CD20 | Reliable signal | NCT02744196: ACR20 response at Week 24 (ALTERRA trial, N=159): Acellbia+MTX 65.7% vs Placebo+MTX 29.4% (p<0.0001); difference 36.3% (95% CI 19.27-53.28%) | |
| Filgotinib (Jyseleca) | Phase 3 | Small molecule | JAK, JAK1 | Reliable signal | NCT02889796: ACR20 at week 12 (primary endpoint): FIL200 76.6% vs placebo 49.9% (difference 26.7%, 95% CI 20.6-32.8, p<0.001); FIL100 69.8% vs placebo 49.9% (difference 19.9%, 95% CI 13.6-26.2, p<0.001) NCT02873936: ACR20 response at Week 12: filgotinib 200mg 66.0%, filgotinib 100mg 57.5%, placebo 31.1%; difference vs placebo 34.9% (95% CI 23.5-46.3) and 26.4% (95% CI 15.0-37.9) respectively, both P<.001 | |
| HLX01 (Hanlikang) | Phase 3 | Monoclonal antibody | CD20 | Reliable signal | No reviewed efficacy summary in this indication | |
| Iguratimod | Phase 3 | — | NF-kB | Partial signal | NCT00965757: ACR20 response at week 24: iguratimod plus methotrexate 69.5% vs placebo plus methotrexate 30.7% (P < 0.001), n=164 vs 88 (Ishiguro et al., Mod Rheumatol 2013). | |
| Levilimab (Ilsira) | Phase 3 | Monoclonal antibody | IL-6 receptor | Reliable signal | NCT04227366: ACR20 response at week 12: 68.6% (levilimab + methotrexate) vs 38.5% (placebo + methotrexate). | |
| Telitacicept | Phase 3 | Protein / enzyme therapeutic | BAFF / APRIL | not yet graded | No reviewed efficacy summary in this indication | |
| Zemprocitinib | Phase 3 | Small molecule | JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| Afimkibart | Phase 2 | Monoclonal antibody | TL1A | not yet graded | No reviewed efficacy summary in this indication | |
| AZD1163 | Phase 2 | Biologic (subtype unspecified) | PAD2 and PAD4 (peptidyl arginine deiminase 2/4) | not yet graded | No reviewed efficacy summary in this indication | |
| Blinatumomab | Phase 2 | Multispecific antibody | CD19 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| CKD-506 | Phase 2 | Small molecule | HDAC6 (Histone deacetylase 6) | Partial signal | NCT04204603: Primary endpoint, change from baseline in DAS28(CRP) at week 12 (full analysis set, n=121): placebo -1.2, CKD-506 200 mg -1.0, 400 mg -1.3, 600 mg -1.2; pre-specified dose-response trend test p > 0.5 (EudraCT 2018-001377-24 posted results). missed | |
| Denosumab (Prolia) | Phase 2 | Monoclonal antibody | RANKL | Partial signal | NCT03239080: Erosion healing at 24 months: 20% (denosumab) vs 6% (placebo), p=0.045. NCT00095498: Primary endpoint (change from baseline in MRI erosion score at 6 months): denosumab 60 mg +0.13 (P=0.118, not significant) vs denosumab 180 mg +0.06 (P=0.007, significant) vs placebo +1.75. Modified Sharp erosion score: 180 mg significant vs placebo at 6 months (P=0.019); both 60 mg (P=0.012) and 180 mg (P=0.007) significant vs placebo at 12 months. | |
| Imeroprubart | Phase 2 | Monoclonal antibody | FcRn | not yet graded | No reviewed efficacy summary in this indication | |
| JAB-8263 | Phase 2 | Small molecule | BET bromodomain proteins (e.g. BRD4) | not yet graded | No reviewed efficacy summary in this indication | |
| Lutikizumab | Phase 2 | Multispecific antibody | IL-1α/IL-1β (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| MK-8690 | Phase 2 | Monoclonal antibody | CD30 ligand (CD30L / CD153) | not yet graded | No reviewed efficacy summary in this indication | |
| Natrunix | Phase 2 | Monoclonal antibody | IL-1 alpha | Partial signal | No reviewed efficacy summary in this indication | |
| Ravagalimab | Phase 2 | Monoclonal antibody | CD40 | not yet graded | No reviewed efficacy summary in this indication | |
| Rosnilimab | Phase 2 | Monoclonal antibody | PD-1 (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-3045 | Phase 2 | Undisclosed | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD0120 | Phase 1/2 | Cell therapy | BCMA / CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-319 | Phase 1 | Antibody–drug conjugate | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-519 | Phase 1 | — | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD5492 | Phase 1 | Multispecific antibody | CD20 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD6912 | Phase 1 | RNA / oligonucleotide | Complement Factor B (CFB) mRNA | Weak signal | No reviewed efficacy summary in this indication | |
| BMS-986454 | Phase 1 | — | PAD4 (peptidylarginine deiminase 4) | not yet graded | No reviewed efficacy summary in this indication | |
| CLN-978 | Phase 1 | Multispecific antibody | CD19 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| CND261 | Phase 1 | Biologic (subtype unspecified) | CD20 x CD3 | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 63 furthest-along competitors are listed; 20 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Upcoming events
(11 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Sarilumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.